A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2006
12/21/2006	CA2611529A1 Imidazo- and triazolopyridines as inhibitors of 11-beta hydroxysteroid dehydrogenase type i
12/21/2006	CA2611523A1 Stable fixed-dose unitary formulations comprising tenofovir, a surfatant and efavirenz
12/21/2006	CA2611500A1 Compositions and methods for treating inflammatory conditions
12/21/2006	CA2611495A1 Aminopyrimidines as kinase modulators
12/21/2006	CA2611493A1 Sulfonamide compounds and uses thereof
12/21/2006	CA2611481A1 Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators
12/21/2006	CA2611480A1 (5z)-5-(6-quinoxalinylmethylidene)-2-[(2,6-dichlorophenyl)amino]-1,3-thiazol-4(5h)-one
12/21/2006	CA2611475A1 Nanoparticulate ebastine formulations
12/21/2006	CA2611470A1 Aminopyrimidines as kinase modulators
12/21/2006	CA2611443A1 Novel tetracyclic tetrahydrofuran derivatives containing a cyclic amine side chain
12/21/2006	CA2611386A1 Use of pde1c and inhibitors thereof
12/21/2006	CA2611378A1 Aminoquinoline and aminoquinazoline kinase modulators
12/21/2006	CA2611376A1 Therapeutic agents
12/21/2006	CA2611263A1 Crystalline forms of a pyrrolotriazine compound
12/21/2006	CA2611242A1 Alkylquinoline and alkylquinazoline kinase modulators
12/21/2006	CA2611240A1 Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators
12/21/2006	CA2611216A1 3-phenylazetidine derivatives as dopamine agonists
12/21/2006	CA2611204A1 Synergistic modulation of flt3 kinase using alkylquinolines and alkylquinazolines
12/21/2006	CA2611190A1 Aqueous sustained-release drug delivery system for highly water-soluble electrolytic drugs
12/21/2006	CA2611030A1 Alpha-(aryl-or heteroaryl-methyl)-beta-piperidinopropanoic acid compounds as orl1-receptor antagonists
12/21/2006	CA2610922A1 Use of allylmercaptocaptopril for treating or preventing obesity and obesity related diseases
12/21/2006	CA2610920A1 Spiro-imidaznaphthyridine derivatives as gastric acid secretion inhibitors
12/21/2006	CA2610903A1 N-(pyridin-2-yl)-sulfonamide derivatives
12/21/2006	CA2610884A1 Inhibitors of checkpoint kinases
12/21/2006	CA2610767A1 Tanaproget compositions containing ethinyl estradiol
12/21/2006	CA2610659A1 Reversible inhibitors of monoamine oxidase a and b
12/21/2006	CA2610588A1 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
12/21/2006	CA2610429A1 Trombin inhibiting 2,4-dioxo-3,4-dihydropyrimidine derivatives
12/21/2006	CA2610428A1 Thrombin inhibiting 2-oxo-1, 2, 5, 6-tetrahydropyridine derivatives
12/21/2006	CA2610422A1 Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
12/21/2006	CA2610412A1 Direct compression formulation of dpp-iv inhibitors and glitazones, and process
12/21/2006	CA2610383A1 Benzofuranyl derivatives as 5-ht6-receptor inhibitors
12/21/2006	CA2610222A1 Steroids having a mixed androgenic and progestagenic profile
12/21/2006	CA2610188A1 Oxadiazole derivatives as dgat inhibitors
12/21/2006	CA2610157A1 Methods of identifying and treating individuals exhibiting mutant kit protein
12/21/2006	CA2609938A1 New oxabispidine compounds for the treatment of cardiac arrhythmias
12/21/2006	CA2609714A1 Pyrrolobenzodiazepine pyridine carboxamides and derivatives as follicle-stimulating hormone receptor antagonists
12/21/2006	CA2609577A1 Benztropinamine analogs as dopamine uptake inhibitors
12/21/2006	CA2608582A1 Chromane substituted benzimidazole derivatives as acid pump antagonists
12/21/2006	CA2607054A1 1, 2-di(cyclic group)substituted benzene derivative
12/21/2006	CA2604078A1 Enteric pharmaceutical formulations of choline salt of fenofibric acid
12/21/2006	CA2599063A1 Acarbose methods and formulations for treating chronic constipation
12/21/2006	CA2596412A1 Anti-connexin compounds and uses thereof
12/21/2006	CA2578844A1 Semi-soft c-class immunostimulatory oligonucleotides
12/21/2006	CA2574090A1 Methods and compositions for inducing innate immune responses
12/21/2006	CA2550704A1 Nicotine transdermal delivery system
12/21/2006	CA2550604A1 Methods for treating smooth muscle disorders using trospium
12/21/2006	CA2550603A1 Methods for treating smooth muscle disorders using trospium
12/20/2006	EP1734119A2 CD16-II variants
12/20/2006	EP1734118A1 Identification of JAK/STAT pathway modulating genes by genome wide RNAi screening
12/20/2006	EP1734064A2 Polymer guanidine derivatives as a cytostatic medicament
12/20/2006	EP1734051A2 Composition and methods for the diagnosis of tumours
12/20/2006	EP1734050A2 Immunization of dairy cattle with GapC protein against streptococcus infection
12/20/2006	EP1734046A1 Radiosensitizer
12/20/2006	EP1734044A1 Process for producing folic acid derivative
12/20/2006	EP1734043A1 Process for the preparation of cefotetan
12/20/2006	EP1734041A2 Platelet ADP receptor inhibitors
12/20/2006	EP1734040A1 Substituted quinazoline or pyridopyrimidine derivative
12/20/2006	EP1734039A1 Aryl urea compounds as BETA-secretase inhibitors
12/20/2006	EP1734037A2 Processes for the preparation of (R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol"
12/20/2006	EP1734031A1 Novel 2-(alpha-n-pentanonyl)benzoetes, their preparation and use
12/20/2006	EP1733758A1 Methods for administration of a farnesyl dibenzodiazepinone
12/20/2006	EP1733743A1 Preventives/remedies for cancer
12/20/2006	EP1733741A2 O/W-emulsions comprising one or several bioquinones and an elevated amount of glycerine
12/20/2006	EP1733738A1 Method of preventing ultraviolet ray-induced apoptosis
12/20/2006	EP1733737A1 Axon regeneration promoter
12/20/2006	EP1733735A2 Methods and products for inducing mucosal immunity
12/20/2006	EP1733734A2 Placental alkaline phosphatase to control diabetes
12/20/2006	EP1733733A1 Regulator for adiponectin receptor expression
12/20/2006	EP1733732A1 Insulin resistance improving agent
12/20/2006	EP1733731A1 New uses of Glycerol derivatives in particular in cosmetics
12/20/2006	EP1733730A2 Immunemodulating oligosaccharides
12/20/2006	EP1733729A1 Use of dipyridamole in combination with acetylsalicylic acid and an angiotensin ii antagonist for stroke prevention
12/20/2006	EP1733728A2 Use of 2-alkoxyphenyl substituted imidazotriazinones as inhibitors of phosphodiesterase
12/20/2006	EP1733727A1 Ferrocenecarboxamide derivatives for use as dopamine D3 ligands for the treatment of CNS disorders
12/20/2006	EP1733726A1 Pharmaceutically active isoindoline derivatives
12/20/2006	EP1733725A1 Farmaceutical formulations comprising at least one HIV protease inhibiting compound
12/20/2006	EP1733724A1 Amino alcohol compound
12/20/2006	EP1733723A1 Medicine capable of inhibiting activation of transcription factor klf5
12/20/2006	EP1733722A1 Memory fixation accelerator
12/20/2006	EP1733721A2 Use of astaxanthin or esters thereof as a phosphodiesterase inhibitor
12/20/2006	EP1733720A1 Composition comprising reduced-form coenzyme q10 and carotenoid compound
12/20/2006	EP1733719A1 Percutaneous absorption-type pharmaceutical preparation using a metal chloride, preferably sodium chloride, for preventing cohesive failure
12/20/2006	EP1733397A2 Anti-infectious hydrogel compositions
12/20/2006	EP1733237A2 Diagnostics and therapeutics for diseases associated with peroxisome proliferative activated receptor alpha (ppara)
12/20/2006	EP1733161A1 Device and method for pneumatic valve control
12/20/2006	EP1733058A2 Iron sucrose complexes and method of manufacture thereof
12/20/2006	EP1733046A1 Combination therapies with epothilones and carboplatin
12/20/2006	EP1733036A2 Cancer prognosis and/or diagnosis method
12/20/2006	EP1733012A1 A composition enriched in diglyceride with conjugated linoleic acid
12/20/2006	EP1732973A1 Crosslinked polymers containing biomass derived materials
12/20/2006	EP1732956A1 Orthoester-protected polyols for low voc coatings
12/20/2006	EP1732953A2 Hydroxyethyl starch
12/20/2006	EP1732948A2 Therapeutic synergy of anti-cancer compounds
12/20/2006	EP1732934A1 Novel thiazolopyrazoles and methods of their use
12/20/2006	EP1732933A1 Compounds and methods for treating dyslipidemia
12/20/2006	EP1732932A1 Crystalline clopidogrel naphthalenesulfonate or hydrate thereof, method for preparing same and pharmaceutical composition containing same
12/20/2006	EP1732929A1 Tricyclic benzopyran compound as anti-arrhythmic agents
12/20/2006	EP1732928A2 Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as orl1-receptor antagonists
12/20/2006	EP1732926A1 Mitotic kinesin inhibitors

1 ... 3958 3959 3960 3961 3962 3963 3964 3965 3966 3967 3968 3969 3970 3971 3972 3973 3974 3975 3976 3977 3978 ... 7860